CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Author's Avatar
Nov 11, 2022
  • Data confirm CV8102's safety and ability to strongly mobilize the immune system against tumors
  • Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023